Heart Failure POC And LOC Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type (Proteomic testing, Metabolomic testing, Genomic testing), By Technology (Microfluidics, Array-based systems, Others), By End Use (Clinics, Hospitals, Home, Assisted living healthcare facilities, Laboratory, Others), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 121.01 Million
CAGR (2026-2031)	8.31%
Fastest Growing Segment	Genomic Testing
Largest Market	North America
Market Size (2031)	USD 195.36 Million

Market Overview

The Global Heart Failure POC And LOC Devices Market will grow from USD 121.01 Million in 2025 to USD 195.36 Million by 2031 at a 8.31% CAGR. Heart Failure Point-of-Care (POC) and Lab-on-Chip (LOC) devices are diagnostic platforms designed to measure cardiac biomarkers, such as natriuretic peptides, directly at the patient's bedside or in community settings without requiring central laboratory processing. The expansion of this market is primarily driven by the escalating global burden of cardiovascular diseases and the critical operational need to reduce hospital readmission rates through rapid triage and treatment optimization. Additionally, the rising geriatric population necessitates decentralized testing capabilities that facilitate immediate clinical decision-making and improve patient compliance outside of acute care facilities.

Despite these strong growth catalysts, the market faces a significant challenge regarding inconsistent reimbursement frameworks, which often fail to adequately cover the higher per-test costs of decentralized diagnostics compared to traditional laboratory methods. This economic barrier is particularly impactful given the sheer volume of patients requiring ongoing management. According to the Heart Failure Society of America, in 2025, approximately 6.7 million adults in the United States were estimated to be living with heart failure. This substantial prevalence underscores the urgent need for cost-effective and accessible diagnostic solutions, yet financial adoption hurdles remain a formidable obstacle to universal implementation.

Key Market Drivers

Technological advancements in microfluidics and biosensor sensitivity are fundamentally reshaping the diagnostic landscape by enabling high-precision cardiac biomarker analysis at the point of care. The integration of high-sensitivity assays into portable platforms allows clinicians to detect minute physiological changes rapidly, facilitating immediate triage and treatment adjustment. This improved diagnostic accuracy is critical for ruling out non-cardiac causes of symptoms in emergency settings without the delays associated with traditional testing. According to Roche Diagnostics, September 2025, in the 'Primary results from the TSIX Study Program', their sixth-generation high-sensitivity Troponin T test demonstrated exceptional precision in identifying acute myocardial events across a study population of over 13,000 participants. Such innovations reduce the reliance on central laboratories, thereby streamlining clinical workflows and decreasing the time to effective intervention for high-risk patients.

The rising global prevalence of heart failure acts as the primary catalyst for market expansion, creating an urgent demand for accessible monitoring solutions. As patient numbers surge, healthcare systems are compelled to adopt decentralized testing to manage the growing burden of chronic cardiac conditions. According to the British Heart Foundation, May 2025, in the 'People's heart health in the UK declining rapidly' report, the number of individuals diagnosed with heart failure in the UK increased by 21% from 2020 to reach a record high of 785,000 in 2024. This escalating incidence underscores the necessity for efficient POC devices that can handle high testing volumes. Furthermore, according to the Heart Failure Society of America, in 2025, heart failure was a contributing cause in 425,147 deaths within the United States during 2022, highlighting the critical need for early detection and management tools.

Download Free Sample Report

Key Market Challenges

Inconsistent reimbursement frameworks present a significant economic barrier that directly impedes the commercial scalability of the Global Heart Failure POC and LOC Devices Market. Although these decentralized diagnostic platforms offer rapid results, their unit production costs generally exceed those of high-throughput central laboratory assays. Insurance payers and national healthcare systems frequently assign reimbursement codes that do not account for this premium, paying providers at the lower standard laboratory rate. Consequently, hospitals and community clinics face a financial disincentive to adopt these devices, as using them often results in a negative operating margin per test performed.

This misalignment between technology costs and payer coverage forces healthcare facilities to limit their procurement of bedside diagnostics, despite the operational need for faster triage. The financial stakes of managing this condition are immense, making cost-containment a primary focus for administrators. According to the Heart Failure Society of America, in 2025, findings revealed that heart failure accounted for 1.2 million primary hospitalizations annually. Given this high volume of acute care episodes, the inability of providers to recover the specific costs of rapid POC testing restricts the market from capitalizing on the demand for faster triage solutions.

Key Market Trends

The Shift Toward Home-Based and Decentralized Patient Monitoring is altering market dynamics by moving diagnostics from acute care settings to the patient’s residence. This transition, enabled by wearable sensors transmitting real-time hemodynamic data, allows for medication titration without physical office visits. Unlike episodic hospital-based testing, continuous physiological monitoring facilitates preemptive intervention, directly addressing the critical need to lower readmission burdens. According to the Society for Cardiovascular Angiography & Interventions, May 2025, in the 'New Studies Highlight Potential of Artificial Intelligence to Improve Outcomes' press release, remote tracking systems utilizing wearable technology led to a 33.1% decrease in the number of heart failure patients requiring hospital care.

Concurrently, the Integration of Artificial Intelligence for Predictive Analytics is enhancing point-of-care devices by transforming raw sensor data into actionable diagnostic insights. Manufacturers are embedding machine learning algorithms into portable readers to identify complex biomarker patterns that precede decompensation, shifting the focus from detection to risk forecasting. This capability improves diagnostic confidence in non-laboratory environments where specialist interpretation is often unavailable. According to News-Medical.Net, November 2025, in the 'Digital and AI innovations in cardiology take center stage' article, a novel AI-enabled digital stethoscope demonstrated a sensitivity and specificity of over 90% for detecting heart conditions, significantly outperforming traditional auscultation methods.

Segmental Insights

Within the Global Heart Failure POC and LOC Devices Market, Genomic Testing has emerged as the fastest-growing segment. This expansion is primarily driven by the industry-wide shift toward personalized medicine, which relies on identifying specific genetic predispositions to tailor effective treatment plans. Innovations in microfluidic technologies now enable rapid molecular analysis directly at the point of care, significantly improving accessibility for clinical users. Consequently, healthcare providers are increasingly utilizing these genomic tools to assess hereditary risk factors and predict disease progression earlier, ensuring more proactive management of heart failure compared to traditional protein-based biomarkers alone.

Regional Insights

North America maintains a leading position in the global heart failure point-of-care and lab-on-chip devices market, driven by a well-established healthcare infrastructure and a rising prevalence of cardiovascular conditions. This dominance is supported by the strong presence of major industry players investing heavily in product development and commercialization. Additionally, supportive regulatory frameworks provided by the U.S. Food and Drug Administration streamline product approvals, while favorable reimbursement structures from the Centers for Medicare & Medicaid Services encourage clinical adoption. These factors collectively create a conducive environment for the sustained growth of diagnostic technologies across the region.

Recent Developments

• In October 2024, Abbott initiated the TEAM-HF clinical trial to evaluate the effectiveness of its CardioMEMS HF System in guiding earlier intervention for patients with worsening heart failure. The global study, set to enroll up to 850 patients, utilizes the implantable pulmonary artery pressure sensor to objectively identify individuals at high risk of mortality who may benefit from advanced therapy options. By measuring pressure changes over time, the device provides continuous data to healthcare providers, facilitating timely treatment decisions. This research underscores the growing role of remote monitoring sensors as a critical component of the heart failure care ecosystem, aiming to improve patient survival and quality of life.
• In August 2024, AISAP obtained FDA clearance for its AI-enabled point-of-care ultrasound (POCUS) software platform, designed to assist in the diagnosis of structural heart disease and heart failure. The cloud-based platform includes modules for computer-assisted diagnosis of valvular pathologies and key cardiac measurements, such as left ventricle ejection fraction. Trained on millions of echocardiography clips, the algorithms enable even inexperienced users to scan and diagnose common heart issues within minutes at the patient's bedside. This development represents a major step in democratizing access to comprehensive cardiac diagnostics across various healthcare environments, from academic centers to remote locations.
• In April 2024, Eko Health received FDA clearance for its Low EF detection AI, a tool designed to assist in the identification of heart failure with reduced ejection fraction. This technology allows healthcare providers to detect a key heart failure indicator in 15 seconds using a digital stethoscope during a routine physical examination. The clearance marks a significant advancement in point-of-care diagnostics, as it transforms a standard medical tool into an AI-powered detection device. By enabling early identification of low ejection fraction in primary care settings, the innovation aims to improve access to care for millions of patients and reduce the reliance on more expensive echocardiography.
• In January 2024, Roche entered into a definitive agreement to acquire the Point of Care technology platform from LumiraDx. The transaction, valued at USD 295 million with an additional potential payment of USD 55 million, aims to integrate the acquired company’s innovative microfluidic technology into the buyer’s diagnostics portfolio. This platform consolidates multiple tests, including those for heart failure, onto a single portable instrument, enabling rapidly accessible diagnostic services in decentralized healthcare settings. The collaboration is expected to transform community-based healthcare by allowing patient-centric solutions that span the entire patient journey, from home to the emergency room.

Key Market Players

• Abbott Laboratories Inc
• Siemens Healthineers AG
• Danaher Corp
• Instrumentation Laboratory Co
• F Hoffmann-La Roche AG
• bioMérieux S.A.
• Abaxis Inc
• Quidel Corp
• Jant Pharmacal Corp
• Trinity Biotech plc

By Test Type	By Technology	By End Use	By Region
Proteomic testing Metabolomic testing Genomic testing	Microfluidics Array-based systems Others	Clinics Hospitals Home Assisted living healthcare facilities Laboratory Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Heart Failure POC And LOC Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Heart Failure POC And LOC Devices Market, By Test Type:

• Proteomic testing
• Metabolomic testing
• Genomic testing

• Heart Failure POC And LOC Devices Market, By Technology:

• Microfluidics
• Array-based systems
• Others

• Heart Failure POC And LOC Devices Market, By End Use:

• Clinics
• Hospitals
• Home
• Assisted living healthcare facilities
• Laboratory
• Others

• Heart Failure POC And LOC Devices Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE